Soligenix Inc (SNGX)

07:30 AM

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - PR Newswire

07:30 AM

May 22, 2026

Soligenix (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates, Stock SlipsTop Trending Breakouts - Newser

May 22, 2026

May 21, 2026

Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

May 21, 2026

May 21, 2026

Soligenix (SNGX) Down -5.08% — Is the Sell-Off Overdone? 2026-05-21Retail Trader Picks - Newser

May 21, 2026

May 17, 2026

Soligenix (SNGX) price target decreased by 60.00% to 6.12 - MSN

May 17, 2026

May 13, 2026

Soligenix (SNGX) Crushes Q4 2025 Estimates — EPS $-0.28 Tops ViewsIntrinsic Value - Newser

May 13, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 11, 2026

SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill

May 11, 2026

May 09, 2026

Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - USA Today

May 09, 2026

May 08, 2026

Soligenix | 424B3: Prospectus - Moomoo

May 08, 2026

May 08, 2026

Soligenix (SNGX) registers 1,054,688 resale shares; Q1 cash $6.03M - Stock Titan

May 08, 2026

May 08, 2026

Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 08, 2026

May 08, 2026

HyBryte CTCL trial halted as Soligenix (SNGX) faces going concern risk - Stock Titan

May 08, 2026

May 08, 2026

Soligenix halts Phase 3 FLASH2 trial for CTCL due to futility, plans data analysis and strategic options. - Pluang

May 08, 2026

May 08, 2026

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - Lelezard

May 08, 2026

May 08, 2026

Soligenix (SNGX) Faces Setback in FLASH2 Study Results - GuruFocus

May 08, 2026

May 08, 2026

Soligenix Releases Q1 2026 Financial Results - AlphaStreet

May 08, 2026

May 08, 2026

Soligenix 1Q Loss/Shr 28c >SNGX - Moomoo

May 08, 2026

May 08, 2026

Soligenix Announces Recent Updates And First Quarter 2026 Financial Results - TradingView

May 08, 2026

May 08, 2026

Soligenix Anticipates HyBryte™ Phase 3 Results in Second Half of 2026, Reports $28.3 Million in Cash - geneonline.com

May 08, 2026

May 08, 2026

Soligenix Q1 net loss narrows on lower expenses - TradingView

May 08, 2026

May 07, 2026

SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment - MSN

May 07, 2026

May 04, 2026

A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo

May 04, 2026

May 03, 2026

Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - USA Today

May 03, 2026

Apr 30, 2026

Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA - RTTNews

Apr 30, 2026

Apr 29, 2026

SNGX phase 3 trial halted on HyBryte - MSN

Apr 29, 2026

Apr 29, 2026

SNGX: FLASH2 Trial Recommended to Stop for Futility - Yahoo Finance

Apr 29, 2026

Apr 29, 2026

Soligenix signals pivotal year with new drug progress - Community News

Apr 29, 2026

Apr 29, 2026

Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives - TipRanks

Apr 29, 2026

Apr 28, 2026

SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment - Stocktwits

Apr 28, 2026

Apr 28, 2026

SNGX Phase 3 Trial Halted on HyBryte - Yahoo Finance

Apr 28, 2026

Apr 28, 2026

Soligenix halts lymphoma drug trial after futility analysis - Investing.com UK

Apr 28, 2026

Apr 28, 2026

Disappointment in Interim Results for Soligenix (SNGX) in Phase 3 Trial - GuruFocus

Apr 28, 2026

Apr 28, 2026

Why Is Soligenix Stock Sinking Tuesday? - Benzinga

Apr 28, 2026

Apr 28, 2026

SNGX - Finviz

Apr 28, 2026

Apr 28, 2026

Soligenix halts lymphoma drug trial after futility analysis By Investing.com - Investing.com Australia

Apr 28, 2026

Apr 28, 2026

HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk - Stock Titan

Apr 28, 2026

Apr 28, 2026

Soligenix Inc Announces Interim Results from Phase 3 Flash2 Trial Evaluating Hybryte in Treatment of Cutaneous T-Cell Lymphoma - marketscreener.com

Apr 28, 2026

Apr 25, 2026

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease (PR Newswire) - Aktiellt

Apr 25, 2026

Apr 25, 2026

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency (PR Newswire) - Aktiellt

Apr 25, 2026

Apr 22, 2026

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - The Globe and Mail

Apr 22, 2026

Apr 21, 2026

Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - NewMediaWire

Apr 21, 2026

Apr 20, 2026

Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - NewMediaWire

Apr 20, 2026